Mettler-Toledo International Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. The filing also reports unaudited fourth-quarter results. Amounts below are in U.S. dollars.
Business context
Mettler-Toledo supplies precision instruments and related services for laboratory, industrial, product-inspection, and food-retailing applications. It operates through five reportable segments: U.S., Swiss, Western European, Chinese, and Other Operations. Laboratory activities generated approximately 54% of 2020 sales, industrial 40%, and retail 6%; no end-customer represented more than 1% of sales.
Financial performance and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Net sales | $3.085 billion | $3.009 billion |
| Gross profit | $1.801 billion | $1.741 billion |
| Gross margin | 58.4% | 57.9% |
| Earnings before taxes | $748.7 million | $681.4 million |
| Net earnings | $602.7 million | $561.1 million |
| Diluted EPS | $24.91 | $22.47 |
| Cash from operating activities | $724.7 million | $603.5 million |
| Capital expenditures | $92.5 million | $97.3 million |
Sales increased 3% in reported dollars and 2% in local currencies. Service revenue rose 3% in reported dollars; product revenue rose 2%. Gross-margin improvement reflected favorable pricing, temporary cost savings, and lower material costs, partly offset by higher transportation costs and mix. The reported effective tax rate was 19.5%, versus 17.7% in 2019; 2019 included a $15.8 million non-cash Swiss tax-reform benefit.
Fourth-quarter 2020 sales were $938.0 million, compared with $844.0 million in the prior-year quarter. Net earnings were $216.3 million versus $192.7 million, and diluted EPS was $9.03 versus $7.84.
At year-end, cash and cash equivalents were $94.3 million, total debt was $1.334 billion, and working capital was $201.9 million. The $1.1 billion revolving credit facility had $602.5 million available; the company reported covenant compliance. Operating cash flow increased, supported by higher earnings and favorable working-capital effects. The company repurchased $775 million of shares in 2020, matching 2019 spending. Shareholders’ equity declined to $282.7 million from $420.8 million.
Material changes and segment trends
- Laboratory sales increased 6% in reported dollars and 5% in local currencies, benefiting particularly from pipettes and biopharma activity related to COVID-19 testing and vaccine development and production preparation.
- Industrial sales declined 1% in both reported dollars and local currencies. Weak product-inspection demand was partly offset by growth in core industrial products, including in China.
- Retail sales declined 3% in reported dollars and 4% in local currencies, reflecting weak conditions and reduced customer investment.
- China external-customer sales increased 6% in reported dollars and local currencies; management reported 7% local-currency growth by destination. Recovery strengthened in the second half after first-quarter COVID-related demand weakness.
- Segment profit increased in all five segments. Total segment profit was $840.7 million, up from $778.1 million; this measure excludes amortization, interest, restructuring, other income or expense, and taxes.
Outlook, commentary, and risks
Management provided no specific numerical sales or EPS guidance in the supplied filing text. It expects to pursue market-share gains, emerging-market expansion, product innovation, margin improvement, and selective bolt-on acquisitions. It anticipates $10 million to $15 million of net investment in new or expanded manufacturing facilities in 2021. Management remained cautious about the uncertain duration and economic effects of COVID-19, while noting expected support from biopharma demand, automation, digitalization, safety, and regulatory-compliance needs.
COVID-19 reduced customer demand and affected some business lines, though operations, production, logistics, and supply were reported as continuing with minimal interruption at year-end. Key risks include further pandemic-related demand or operational disruption; economic downturns and customer capital-spending delays; competitive and pricing pressure; China concentration and international, currency, trade, and repatriation risks; supply-chain and single-site production disruptions; cybersecurity and systems risks; and debt, refinancing, and interest-rate exposure. Management identified no legal proceeding expected to have a material adverse effect. It disclosed an ongoing New Jersey groundwater-monitoring obligation, with estimated compliance costs of approximately $0.4 million over the next several years.
Other notable items include $10.5 million of restructuring charges in 2020 and $13.8 million of net other income, including $12.2 million of non-service pension benefits. The CEO was scheduled to step down on April 1, 2021, with Patrick Kaltenbach designated to succeed him. The auditor issued an unqualified opinion on the financial statements and internal control over financial reporting; the audit identified valuation of deferred tax assets as a critical audit matter.
Key facts for investors to verify
- Whether COVID-19-related biopharma demand and second-half recovery persist, and how non-laboratory markets perform.
- The sustainability of margin improvement given temporary cost savings, transportation costs, product mix, and competitive pricing.
- Debt maturities, available revolver capacity, refinancing plans, and the effects of currency movements and LIBOR transition.
- Cash-flow allocation between substantial share repurchases, capital spending, acquisitions, and debt reduction.
- Assumptions supporting deferred-tax-asset realization, pension obligations, and potential future environmental or other contingencies.